Abstract
Natalizumab (Tysabri) is the first monoclonal antibody indicated for the treatment of active relapsing-remitting multiple sclerosis. Natalizumab is reserved for hospital use. Strict monitoring is necessary to detect side effects associated with the perfusion of the product, possible inefficacy of the treatment, and, more rarely, infectious complications, some of which (for example, progressive multifocal leukoencephalitis) are severe. Rigorous collection of efficacy and tolerance data will make it possible to assess the impact of this treatment on the natural history of multiple sclerosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
